Guojia Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guojia Ma has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chengluan Xuan
Department of Anesthesiology, First Medical Hospital of Jilin University, Jilin, China
1 shared publication - Liang Zhang
Department of Cardiovascular Surgery, Second Hospital of Jilin University, Jilin University, Jilin, China
1 shared publication - Ning Dong
The emergency department of the No.1 hospital of Jilin University, Jilin University, Jilin, China
1 shared publication - Rihao Xu
Department of Cardiovascular Surgery, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, Jilin, 130041, People's Republic of China
1 shared publication - Wen Yan
Department of Cardiovascular Surgery, Second Hospital of Jilin University, Jilin University, Jilin, China
1 shared publication - Zijian Wang
Internal Medicine, Xiamen174 Hospital, Xiamen, China
1 shared publication
Latest Publications
- Open Access
- 2 September 2014
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 9 (1) , 1-8
Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations
Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of platelets and rFVIIa during operations for acute type A aortic dissections. Between May 2009 and August 2012, 71 patients with acute type A dissections who underwent emergency surgery were prospectively included and allocated to one of the following two intervention groups for hemostasis: 3 units platelets combined with 2.4 mg rFVIIa (n = 25), and conventional methods (n = 46). The patients who received the combination of platelets and rFVIIa required fewer transfusions of red blood cells (6.2 ± 3.1 units vs 9.8 ± 2.8 units; p < 0.05), fresh frozen plasma (736.9 ± 178.3 ml vs 1264.3 ± 245.2 ml, p < 0.05), platelet concentrates (3 units vs 5.0 ± 1.8 units, p < 0.001), and cryoprecipitate (2.8 ± 0.9 units vs 8.2 ± 2.3 units, p < 0.05). These patients also required less time for sternal closure (76.9 ± 17.2 min vs 102.3 ± 10.7 min, p < 0.05) compared with the conventional therapy patients. There was no statistically significant difference in the incidence of serious adverse events between these two groups. Using a combination of platelets and rFVIIa is an effective strategy for achieving hemostasis during acute type A dissection surgery. This hemostatic strategy does not appear to be associated with an increase in postoperative adverse events.
- 2 September 2014
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 9 (1) , 1-8
Open AccessCombination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations
Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of platelets and rFVIIa during operations for acute type A aortic dissections. Between May 2009 and August 2012, 71 patients with acute type A dissections who underwent emergency surgery were prospectively included and allocated to one of the following two intervention groups for hemostasis: 3 units platelets combined with 2.4 mg rFVIIa (n = 25), and conventional methods (n = 46). The patients who received the combination of platelets and rFVIIa required fewer transfusions of red blood cells (6.2 ± 3.1 units vs 9.8 ± 2.8 units; p < 0.05), fresh frozen plasma (736.9 ± 178.3 ml vs 1264.3 ± 245.2 ml, p < 0.05), platelet concentrates (3 units vs 5.0 ± 1.8 units, p < 0.001), and cryoprecipitate (2.8 ± 0.9 units vs 8.2 ± 2.3 units, p < 0.05). These patients also required less time for sternal closure (76.9 ± 17.2 min vs 102.3 ± 10.7 min, p < 0.05) compared with the conventional therapy patients. There was no statistically significant difference in the incidence of serious adverse events between these two groups. Using a combination of platelets and rFVIIa is an effective strategy for achieving hemostasis during acute type A dissection surgery. This hemostatic strategy does not appear to be associated with an increase in postoperative adverse events.